UK Breakthrough in Migraine Treatment

LIEGE, Belgium, Nov. 8, 2011 /CNW/ - PREMICE clinical trial proves Cefaly(R) medical device efficacy in migraine prevention and points out that Cefaly(R) has the best safety-efficacy ratio compared to other treatments.

On Monday 7th of November a press conference took place in Liege Science Park. Professor Jean Schoenen, principal investigator, neurologist and professor at Liege University (Belgium) presented the results of PREMICE (Prevention Migraine Cefaly) a multicenter randomized double-blind placebo controlled clinical trial for migraine prevention with the Cefaly(R) neurostimulator.

The clinical trial was conducted in 5 Belgian university hospitals on 67 patients. The results prove the efficacy of the Cefaly(R) compared to placebo for migraine prevention. At 3 months of treatment the 50% responder rate was significantly greater in the Cefaly(R) group (38,1%) than in the placebo group (12,1%). Seventy percents of patients declared they were satisfied or very satisfied with the Cefaly(R) treatment. The drug consumption reduction is very impressive in the Cefaly(R) group (-37%) compared to the placebo group (+0.5%). Cefaly(R) responder group drug consumption reduction was -75%!

Without noticeable side effects or contraindications, Cefaly(R) is very safe. Cefaly(R) has a similar efficacy than preventative drugs, but without side effects. Consequently, Cefaly(R) has the best safety-efficacy ratio of all migraine treatments.

Prof. Schoenen: "This clinical trial has been implemented according to the highest quality standard and it proves that Cefaly(R) is efficient for migraine prophylaxis. Efficacy is similar with the most efficient preventative drugs but with the great advantage of having no side effects."

Cefaly(R) is an innovative medical device protected by a series of patents. This is the first cranial external neurostimulation device on the market. Cefaly(R) neurostimulation is applied to the upper branch of the trigeminal nerve. A self-adhesive electrode is applied on the forehead and the device is placed on this electrode in the position of a pair of glasses. Very accurate pulses are transmitted through the electrode to the nerve endings of the trigeminal nerve.

STX-Med Company is a startup based in Liege (Belgium), which launched the Cefaly(R) technology project in 2005. The company STX-Med is ISO Medical. Cefaly(R) device has the medical CE-marked. It is available on the European market for 295 EUR and in Canada as well.

http://www.cefaly.com/

SOURCE STX-Med

For further information:

STX-Med, ZI des Hauts Sarts, 4eme Avenue N°5, B-4040, Herstal, Liège, Belgium, Phone: +32-43676722, Fax: +32-43676702, info@stx-med.com; Press Contact Dr Pierre Rigaux, Mobile: +32-475413698, p.rigaux@stx-med.com

Profil de l'entreprise

STX-Med

Renseignements sur cet organisme


FORFAITS PERSONNALISÉS

Jetez un coup d’œil sur nos forfaits personnalisés ou créez le vôtre selon vos besoins de communication particuliers.

Commencez dès aujourd'hui .

ADHÉSION À CNW

Remplissez un formulaire d'adhésion à CNW ou communiquez avec nous au 1-877-269-7890.

RENSEIGNEZ-VOUS SUR LES SERVICES DE CNW

Demandez plus d'informations sur les produits et services de CNW ou communiquez avec nous au 1‑877-269-7890.